ROYALTY PHARMA
Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma does not discover, develop, manufacture or market products. Instead, the Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with research instit... utions, inventors and biotechnology & pharmaceutical companies since 1996, and now owns royalty interests in forty four approved and marketed biopharmaceutical products and seven products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency ("EMA”).
ROYALTY PHARMA
Industry:
Biotechnology Manufacturing Pharmaceutical
Founded:
1996-01-01
Status:
Active
Contact:
212-883-0200
Total Funding:
0
Technology used in webpage:
SPF Google Font API Microsoft Exchange Online Amazon Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS GoDaddy DNS Apache 2.4
Similar Organizations
Welmedix Consumer Healthcare
Welmedix Consumer Healthcare develops and markets pharmaceutical products.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Onspira Therapeutics
Onspira Therapeutics operates as a clinical-stage biopharmaceutical company.
Current Advisors List
Board_member
Board_member
2020-08-01
Current Employees Featured
Sandy Balkin SVP Strategy and Analytics @ Royalty Pharma
SVP Strategy and Analytics
2021-01-01
Pablo Legoretta CEO & Founder @ Royalty Pharma
CEO & Founder
1996-09-01
George Lloyd Executive Vice President, Investments and General Counsel @ Royalty Pharma
Executive Vice President, Investments and General Counsel
Jim Reddoch Chief Scientific Officer, Executive Vice President, Head of Research and Investments @ Royalty Pharma
Chief Scientific Officer, Executive Vice President, Head of Research and Investments
2008-07-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-11-07 | Eisai | Eisai acquired by Royalty Pharma | 330 M USD |
Investors List
General Atlantic
General Atlantic investment in Private Equity Round - Royalty Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-01 | Cytokinetics | Royalty Pharma investment in Post-IPO Debt - Cytokinetics | 450 M USD |
| 2022-05-18 | ApiJect | Royalty Pharma investment in Private Equity Round - ApiJect | 111 M USD |
| 2021-11-22 | BioCryst Pharmaceuticals | Royalty Pharma investment in Post-IPO Equity - BioCryst Pharmaceuticals | 350 M USD |
| 2020-12-07 | BioCryst Pharmaceuticals | Royalty Pharma investment in Post-IPO Debt - BioCryst Pharmaceuticals | 325 M USD |
| 2019-11-07 | Epizyme | Royalty Pharma investment in Post-IPO Equity - Epizyme | 100 M USD |
More informations about "Royalty Pharma"
Royalty Pharma - Wikipedia
Royalty Pharma is a private equity investor firm founded in 1996. It purchases the rights to royalties on future drug sales. It claims to own partial rights to 7 of the top 30 selling drugs in …See details»
Our firm | Royalty Pharma
Nov 1, 2023 Founded in 1996, Royalty Pharma has pioneered the royalty funding market and continued to innovate in life science funding. Life sciences …See details»
Investors - Royalty Pharma
Nov 1, 2023 NEW YORK, NY, March 27, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on …See details»
Royalty Pharma simplifies corporate structure with $1.1 bln deal
Jan 10, 2025 Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages the healthcare firm's operations, as it seeks to …See details»
Royalty Pharma simplifies corporate structure with $1.1 billion deal
Jan 10, 2025 Royalty Pharma said its decision follows feedback from investors that the current structure made it difficult to invest in the healthcare firm, and shifting to an internal …See details»
Royalty Pharma - The Org
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research …See details»
Royalty Pharma Org Chart + Executive Team - The Official Board
The org chart of Royalty Pharma contains its 34 main executives including Pablo Legorreta, Terrance Coyne, George Lloyd and Kristin Stafford.See details»
Royalties in pharma: A closer look at the company which owns a …
TLDR; Royalty agreements are on the rise, and threaten to eat into big pharma’s top-line and limit their role in the biopharma ecosystem. Once little-known outside financing circles, Royalty …See details»
Royalty Pharma - Crunchbase Investor Profile
Royalty Pharma does not discover, develop, manufacture or market products. Instead, the. Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with …See details»
Board of directors - Royalty Pharma
Prior to founding Royalty Pharma, Pablo was an investment banker at Lazard Frères in Paris and New York. Close . Bonnie Bassler, PhD. View Bio Bonnie Bassler, PhD. Bonnie Bassler, PhD has been a member of our board of …See details»
Royalty Pharma - Craft
Oct 29, 2024 Royalty Pharma is a company operating as a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with …See details»
Royalty Pharma - Leadership Team - The Org
Other teams at Royalty Pharma. View all. BB. CE. ES +5. Board of Directors. 8 members. The Org helps you hire great candidates. It takes less than ten minutes to set up your company …See details»
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics
18 hours ago For the quarter ended March 2025, Royalty Pharma (RPRX) reported revenue of $839 million, up 17% over the same period last year. EPS came in at $1.06, compared to …See details»
Royalty Pharma - Overview, News & Similar companies - ZoomInfo
May 9, 2024 Who is Royalty Pharma. Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical …See details»
Royalty Pharma Reports First Quarter 2025 Results - Morningstar
1 day ago Amounts may not add due to rounding. Royalty Transactions. In February 2025, Royalty Pharma entered into an R&D funding arrangement with Biogen to provide up to $250 …See details»
Royalty Pharma Announces Transformative Step in Company’s …
Jan 10, 2025 Royalty Pharma will acquire the Manager for approximately 24.5 million shares of Royalty Pharma equity that will vest over 5 to 9 years, approximately $100 million in cash [1], …See details»
Royalty pharma projects 6-12% growth in 2025 portfolio receipts …
16 hours ago Gain insights into Royalty Pharma's Q1 2025 results, featuring 12% growth in receipts, expanded pipeline, capital returns, and raised full-year guidance.See details»
Royalty Pharma - Contacts, Employees, Board Members
Royalty Pharma has 5 current employee profiles, including Senior Vice President and Chief Technology Officer Eric Schneider. Royalty Pharma has 4 board members and advisors, …See details»
2023 Royalty Pharma – PCF Young Investigator Award
2023 Royalty Pharma – PCF Young Investigator Award. Share This Page. Copy Email Print X (Twitter) Facebook LinkedIn. Investigating Tumor and Immune Cell Dysregulation for the …See details»
Royalty Pharma Reports First Quarter 2025 Results
1 day ago Royalty Pharma’s liquidity and capital resources are summarized below: As of March 31, 2025, Royalty Pharma had cash and cash equivalents of $1.1 billion and total debt with …See details»